Mustafa S Shahzad, Rider Nicholas L, Jolles Stephen
Rochester Regional Health, Division of Allergy, Immunology, and Rheumatology, University of Rochester School of Medicine and Dentistry, Rochester, NY; Liberty University College of Osteopathic Medicine and the Liberty Mountain, Chair, Division of Clinical Informatics; Associate Professor of Pediatrics, Allergy-Immunology Medical Group, Rochester, NY.
Liberty University College of Osteopathic Medicine and the Liberty Mountain Medical Group, Lynchburg, Va.
J Allergy Clin Immunol Pract. 2022 Dec;10(12):3088-3096. doi: 10.1016/j.jaip.2022.08.025. Epub 2022 Aug 29.
Individuals with primary immunodeficiency (PIDD) experience not only infectious complications but also immune dysregulation leading to autoimmunity, inflammation, and lymphoproliferative manifestations. Management of these complications often requires treatment with additional immunosuppressive medications, which pose an additional risk of infectious complications. Immunosuppression in individuals with PIDD therefore requires careful assessment and consideration of risks and benefits. Medications should be closely monitored, and strategies for risk mitigation of adverse events considered, such as exposure reduction, appropriate vaccination, use of antibiotics/antivirals, and optimization of immunoglobulin replacement therapy. In a subset of individuals who are not tolerating immune modulation or experiencing disease progression despite appropriate interventions, hematopoietic stem-cell transplantation is a management option.
原发性免疫缺陷(PIDD)患者不仅会出现感染性并发症,还会出现免疫失调,导致自身免疫、炎症和淋巴增殖性表现。这些并发症的管理通常需要使用额外的免疫抑制药物进行治疗,这会带来额外的感染性并发症风险。因此,对PIDD患者进行免疫抑制需要仔细评估和权衡风险与益处。应密切监测药物,并考虑减轻不良事件风险的策略,如减少接触、适当接种疫苗(使用抗生素/抗病毒药物)以及优化免疫球蛋白替代疗法。对于一部分尽管采取了适当干预措施仍无法耐受免疫调节或病情仍在进展的患者,造血干细胞移植是一种管理选择。